"How I treat” based on the new/updated classification systems

During the MDS Hub Steering Committee meeting, held on October 26, 2023, Pierre Fenaux chaired a “How I treat” discussion based on the new/updated classification systems in myelodysplastic syndromes (MDS), with contributions from Theo de Witte and Yasushi Miyazaki.

Fenaux highlights the differences between the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemia, outlining the consequences of these differences in the management of MDS. He also discusses the Molecular International Prognostic Scoring System and the impact of a patient's mutational profile on treatment decision-making. Fenaux continues by describing the updates in the International Working Group 2023 response criteria for higher-risk (MDS). To conclude, the committee discusses factors that influence transplant decision-making and the use of azacitidine and venetoclax as a bridge to transplant.